Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203145 | 0.81 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL12036858 | 0.79 | — | — | |
| SCHEMBL12452329 | 0.79 | PDE4A (0.31) | IRAK4 | |
| SCHEMBL12036731 | 0.78 | IRAK4 (0.56) | IRAK4 | |
| SCHEMBL17213486 | 0.77 | RAB9A (0.33) | IRAK4 | |
| SCHEMBL802358 | 0.76 | IRAK4 (0.30) | IRAK4 | |
| SCHEMBL12037688 | 0.76 | IRAK4 (0.71) | IRAK4 | |
| SCHEMBL15982444 | 0.75 | — | — | |
| SCHEMBL12036749 | 0.75 | — | — | |
| SCHEMBL12036864 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433621-B2 | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2536410-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME (US) | 2015-09-23 | — | — | EP | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2011103441-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | IRAK4 706/4885 |
| US-20140242027-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | IRAK4 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.